Your search returned 9 results.

Results
	1.	Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. [electronic resource] by Komaki, Y Yamada, A Komaki, F Sakuraba, A Producer: 20171220 In: Alimentary pharmacology & therapeutics vol. 46 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. [electronic resource] by Komaki, Y Komaki, F Yamada, A Micic, D Ido, A Sakuraba, A Producer: 20190409 In: Clinical pharmacology and therapeutics vol. 103 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. [electronic resource] by Komaki, Y Yamada, A Komaki, F Micic, D Ido, A Sakuraba, A Producer: 20171220 In: Alimentary pharmacology & therapeutics vol. 45 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. [electronic resource] by Komaki, Y Yamada, A Komaki, F Micic, D Ido, A Sakuraba, A Producer: 20170907 In: Alimentary pharmacology & therapeutics vol. 45 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. [electronic resource] by Sato, T Nakai, T Tamura, N Okamoto, S Matsuoka, K Sakuraba, A Fukushima, T Uede, T Hibi, T Producer: 20051129 In: Gut vol. 54 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. [electronic resource] by Ananthakrishnan, A N Sakuraba, A Barnes, E L Pekow, J Raffals, L Long, M D Sandler, R S Producer: 20171204 In: Alimentary pharmacology & therapeutics vol. 46 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. [electronic resource] by Kanatani, A Kanno, T Ishihara, A Hata, M Sakuraba, A Tanaka, T Tsuchiya, Y Mase, T Fukuroda, T Fukami, T Ihara, M Producer: 20000106 In: Biochemical and biophysical research communications vol. 266 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors. [electronic resource] by Kannoa, T Kanatani, A Keen, S L Arai-Otsuki, S Haga, Y Iwama, T Ishihara, A Sakuraba, A Iwaasa, H Hirose, M Morishima, H Fukami, T Ihara, M Producer: 20010719 In: Peptides vol. 22 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. [electronic resource] by Matsuoka, K Inoue, N Sato, T Okamoto, S Hisamatsu, T Kishi, Y Sakuraba, A Hitotsumatsu, O Ogata, H Koganei, K Fukushima, T Kanai, T Watanabe, M Ishii, H Hibi, T Producer: 20041004 In: Gut vol. 53 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)